Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight

NCT07441252 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07441252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07441252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 5, 2026
Completion date
November 17, 2027
Enrollment
180 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity and elevated liver fat